

August 19, 2014

Corporation: Asahi Intecc Co., Ltd.
TSE 2nd section and NSE 2nd section; Code number: 7747
Representative: Masahiko Miyata, President & CEO
Contact: Mizuho Ito, Manager of Corporate Strategic Office
(TEL. +81-52-768-1211)

Corporation: Boston Scientific Corporation
Representative: Kevin Ballinger, Global President, Interventional Cardiology
Contact: Kenichi Kitawaki, Corporate Marketing, Boston Scientific Japan K.K.
(TEL. +81-3-6853-6946) (CEL. +81-80-2414-4574)

Boston Scientific and Asahi Intecc Co., Ltd. Launch Business Alliance

Both parties agree to program for development of advanced FFR (fractional flow reserve) wires and further improvement of Boston Scientific's Rotablator™ and RotaWire™

Asahi Intecc Group announces that Boston Scientific Corporation (hereinafter "Boston Scientific") and Asahi Intecc Co., Ltd. (hereinafter "Asahi Intecc") will launch a business alliance with regards to FFR wires and RotaWire™ Atherectomy Guidewire

1. Details of Business Alliance

Boston Scientific (New York Stock Exchange: BSX) and Asahi Intecc (TSE 2nd section and NSE 2nd section; code number: 7747) announced a joint program to develop and produce FFR wires (Note 1). The purpose of starting this program is for both companies to develop FFR wires with dramatically improved operability compared to conventional FFR wires.

The FFR market is a new growing field in international cardiology with a global scale of more than 250 million USD and with a double digit growth rate. Percutaneous transluminal coronary angioplasty (PCI treatment) using FFR is excellent for its cost effectiveness and at the same time decreases the rate of MACEs (major adverse cardiac events) per year. The FFR wire to be jointly developed will be able to be used by Boston Scientific's Polaris Multi-Modality Imaging System.

Moreover, as part of the program, both parties have agreed to collaborate on the improvement and enhancement of RotaWire™ Atherectomy Guidewire (hereinafter "RotaWire" (Note 2)), a state-of-the-art guide wire designed by Boston Scientific, whereby Asahi Intecc will supply major components to Boston Scientific. In order to give Boston Scientific's state-of-the-art RotaWire improved operability and control capabilities, Asahi Intecc will supply components. RotaWire is used in the coronary atherectomy system which leads the market and is used for treatment of coronary artery calcification lesions. Through the introduction of the components to be supplied by Asahi Intecc it is expected that performance of RotaWire will advance, contributing to betterment of treatment of complex coronary artery diseases.

In addition, Boston Scientific is planning to start production of these special two wires in 2015.

"We expect our collaboration with Asahi Intecc to help improve care for patients with coronary artery disease and strengthen our interventional cardiology portfolio," said Kevin Ballinger, Global

President, Interventional Cardiology, Boston Scientific. "The Asahi Intecc expertise in guide wire technology is unparalleled. By leveraging the strengths of our technologies, we have the opportunity to create truly differentiated products."

"Boston Scientific has advanced sensor and atherectomy technologies. By combining these technologies with our expertise in wires and components, we believe the manipulability of these products will improve dramatically," said Masahiko Miyata, President and Chief Executive Officer, Asahi Intecc. "Through our collaboration with Boston Scientific, we are confident that we will be able to help improve outcomes for patients."

(Note 1): FFR wires are wires with imbedded sensors that measure the pressure gradient of blood flow around stenosed sections of the coronary artery and speculate how much blood flow is being inhibited and how severe the lesion is as a result of the stenosis. This measured index is one of the factors in deciding whether or not coronary artery treatment is necessary.

(Note 2): RotaWire is used to guide the treatment equipment (rotablator) which scrape off stenotic lesions in the artery with a diamond drill rotating at a high speed.

2. Overview of the Companies

1) Boston Scientific Corporation

- 1) Line of business Development, production and sale of medical devices
- 2) Headquarters Marlborough, Massachusetts, USA
- 3) Representative Kevin Ballinger, Global President, Interventional Cardiology

2) Asahi Intecc Co., Ltd.

- 1) Line of business Development, manufacturing and sale of medical devices
Development, manufacturing and sale of ultrafine stainless wire rope and terminal processed wire ropes, etc.
- 2) Headquarters 1703 Wakita-cho, Moriyama-ku, Nagoya-shi, Aichi, Japan
- 3) Representative Masahiko Miyata, President & CEO

3. Impact on Business Performance

The impact of the business alliance on business performance will be minimal.

While the business alliance is expected to contribute to improving the business performance of both companies, there is no impact on the performance forecast for the fiscal year ending June 2015 and the fiscal year ending June 2016 as in the new medium-term management plan "Global Expansion 2018" announced by Asahi Intecc Co., Ltd. on August 12, 2014.

All forward-looking statements in this press release are determined by the company based on information available as of the date of the release and therefore include potential risks and uncertainties. The actual business performance may differ from what is indicated due to changes of various factors. As such, please be aware that actual results, etc. may differ significantly from the details indicated in this press release.